Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management

EP4536691A4Pending Publication Date: 2026-06-03ZYDUS LIFESCIENCES LTD
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
ZYDUS LIFESCIENCES LTD
Filing Date
2023-06-06
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Current Semaglutide injectable formulations for type 2 diabetes and weight management are available in disposable single-use pens, leading to increased treatment costs and environmental waste, as well as stability issues with higher phenol concentrations, necessitating single-use pens and fixed doses.

Method used

A reusable multi-dose pen injector device delivering variable doses of Semaglutide with a liquid pharmaceutical composition of 3 mg/mL to 25 mg/mL Semaglutide and 0.11% w/w to 0.5% w/w phenol, optimized for stability and cost-effectiveness, allowing multiple dose administration with replaceable cartridges.

Benefits of technology

The solution provides a cost-effective, environmentally friendly, and stable delivery of Semaglutide, enabling multiple variable doses from a single device, improving patient compliance and reducing waste, while maintaining therapeutic efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000013_0001
    Figure IMGF000013_0001
  • Figure IMGF000013_0002
    Figure IMGF000013_0002
  • Figure IMGF000014_0001
    Figure IMGF000014_0001
Patent Text Reader

Abstract

The aim of the invention is to provide liquid composition of Semaglutide with phenol in concentration of 0.11% w / w to 0.5% w / w which will enhance stability of the composition. Also provided herein a process for the preparation of composition of Semaglutide and method of using the same for treating diabetes and obesity.
Need to check novelty before this filing date? Find Prior Art